| (INR) | Jun 2026 | Y/Y change |
|---|---|---|
| Revenue | 40.18B | — |
| Operating expense | — | — |
| Net income | 4.83B | — |
| Net profit margin | — | — |
| Earnings per share | — | — |
| EBITDA | — | — |
| Effective tax rate | — | — |
Over the past year, GLENMARK.NS returned +19.9% with dividends reinvested.
| Period | Total return |
|---|---|
| YTD | +13.9% |
| 1 year | +19.9% |
| 5 years | +359.0% |
| 10 years | +194.3% |
| All-time high | ₹2,406.30 (Apr 2026) |
Returns are total returns and include reinvested dividends. The all-time high is the highest monthly closing price on record.
See what ₹1,000 in GLENMARK.NS would be worth today ›Yes. Glenmark Pharmaceuticals Limited paid 2 dividends over the past 12 months. The most recent was ₹2.50 per share on Oct 3, 2025. The dividend yield is 0.32%.
Glenmark Pharmaceuticals Limited is part of the Healthcare sector.
Glenmark Pharmaceuticals Limited has a market cap of 674.71B INR, based on the latest quote.
Glenmark Pharmaceuticals Limited is expected to report earnings around Oct 30, 2026. That date is an estimate and has not been confirmed by the company.
